EXKIVITY
PeakNDAORALCAPSULEPriority Review
Approved
Sep 2021
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 14h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EXKIVITY is an oral small-molecule capsule approved by the FDA in September 2021 under Takeda's portfolio. The mechanism of action and therapeutic indication are not publicly disclosed in available data. It represents a novel chemical entity in active commercial distribution.
$10MPart D
Peak8.8 years to LOEProduct is at peak lifecycle stage with modest Part D uptake (449 claims in 2023), suggesting early-to-mid commercial phase with opportunity for field expansion and brand-building roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
EXKIVITY currently shows zero linked job postings, indicating either early staffing completion or limited public hiring visibility. Working on this product at peak lifecycle stage offers exposure to brand-building, field execution, and payer management in a stable, patent-protected environment.
Brand ManagerField Sales Representative
Worked on EXKIVITY at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.